HIV/HCV-coinfected patients remain at increased risk for hepatocellular carcinoma even after achieving sustained virologic response; ongoing surveillance is warranted despite successful HCV treatment.
Hepatocellular carcinoma (HCC) is a complication of hepatitis C virus (HCV) infection. Now that HIV-infected patients are living longer, those with HCV coinfection are experiencing increased morbidity and mortality from HCV complications such as cirrhosis and HCC. Effective HCV treatment decreases the risk for developing HCC; however, for patients who have already developed cirrhosis, such risk is not entirely eliminated.
In a recent retrospective cohort study, investigators in Spain analyzed 167 cases of HCC in HIV/HCV-coinfected patients. Sixty-five (39%) of these patients had received HCV treatment before HCC was diagnosed, including 13 who had achieved sustained virologic response (SVR) a median of 28 months before the diagnosis.
All 13 p…
Reviewing Author
DisclosuresGrant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; NIH/National Institute on Drug Abuse
Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes; Vaccines
Leadership Positions in Professional SocietiesInternational Antiviral Society–USA (Board of Directors); Infectious Diseases Society of America (Past President)
DisclosuresGrant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; NIH/National Institute on Drug Abuse
Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes; Vaccines
Leadership Positions in Professional SocietiesInternational Antiviral Society–USA (Board of Directors); Infectious Diseases Society of America (Past President)